The irritable bowel syndrome

New England Journal of Medicine

Volumn 344, Issue 24, 2001, Pages 1846-1850

  Horwitz, Brenda J ^a   Fisher, Robert S ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDIARRHEAL AGENT; ANTINOCICEPTIVE AGENT; ATROPINE PLUS DIPHENOXYLATE; CASCARA; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; DESIPRAMINE; DICYCLOVERINE; HYOSCYAMINE; LACTULOSE; LAXATIVE; LOPERAMIDE; MACROGOL; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PRUCALOPRIDE; SENNA EXTRACT; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SORBITOL; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIET RESTRICTION; DRUG INDICATION; HEALTH CARE COST; HUMAN; IRRITABLE COLON; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANTIDIARRHEALS; CATHARTICS; COLONIC DISEASES, FUNCTIONAL; DIETARY FIBER; HUMANS; PARASYMPATHOLYTICS;

EID: 0035859198     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106143442407     Document Type: Review

References (50)

1. Electrogalvinism in a particular affliction of mucous membrane of the bowels
2. Functional bowel disorders and functional abdominal pain
3. Irritable bowel syndrome
4. Irritable bowel syndrome in office-based practice in the United States
5. Irritable bowel syndrome: A technical review for practice guideline development
6. Psychosocial aspects of the functional gastrointestinal disorders
7. Nongastrointestinal disorders in the irritable bowel syndrome
8. Primary fibromyalgia and the irritable bowel syndrome: Different expressions of a common pathogenetic process
9. Medical costs in community subjects with irritable bowel syndrome
10. Experimental studies on the irritable colon
11. Evidence that abnormal myoelectrical activity produces colonic motor dysfunction in the irritable bowel syndrome
12. The irritable bowel syndrome: A paroxysmal motor disorder
13. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
14. Irritable bowel syndrome: Physiological and psychological differences between diarrhea-predominant and constipation-predominant patterns
15. Dysmotility of the small intestine in irritable bowel syndrome
16. Central processing of rectal pain in IBS patients: An fMRI study
17. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distension
18. Dysfunction of the motivational-affective pain system in patients with IBS: Pet brain imaging in response to rectal balloon distension
19. Regional cerebral activity in normal and pathological perception of visceral pain
20. Alterations in colonic function in man under stress. II. Experimental production of sigmoid spasm in healthy persons
21. Psychosocial factors in the irritable bowel syndrome: A multivariate study of patients and nonpatients with irritable bowel syndrome
22. Symptoms of psychologic distress associated with irritable bowel syndrome: Comparison of community and medical clinic samples
23. Sexual and physical abuse and gastrointestinal illness
24. Roles played by 5-hydroxytryptamine in the physiology of the bowel
25. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study
26. 5-Hydroxytryptamine and enterochromaffin cells in the irritable bowel syndrome
27. Post-dysenteric colitis
28. The irritable colon syndrome: A study of the clinical features, predisposing causes, and prognosis in 130 cases
29. Irritable bowel syndrome - Post salmonella infection
30. The role of psychological and biological factors in postinfective gut dysfunction
31. Endoscopy in the evaluation of dyspepsia
32. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
33. Calcium polycarbophil compared with placebo in irritable bowel syndrome
34. Ispaghula therapy in irritable bowel syndrome: Improvement in overall well-being is related to reduction in bowel dissatisfaction
35. Double blind study of ispaghula in irritable bowel syndrome
36. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
37. Symptom relief with amitriptyline in the irritable bowel syndrome
38. Psychotropic medications for the treatment of functional gastrointestinal disorders
39. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist
40. Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist
41. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome: A multicenter dose-response study
42. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
43. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
44. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit
45. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
46. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
47. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)
48. Prucalopride (PRU) improves bowel movement (BM) frequency and symptoms (SX) in patients (PTS) with chronic constipation (CC): Results of two double-blind, placebo-controlled trials
49. Effects of prucalopride (PKU) on colonic transit in patients (PTS) with chronic constipation (CC)
50. The irritable bowel syndrome: Review and a graduated multicomponent treatment approach